On very low LDL, the myth of “too low,” and what happens to patients when specialists can’t agree on the evidence *Optimized Medicine | Anthony Pick MD, CDCES, CCD
There are moments in clinical medicine that stay with you not because something went wrong, but because something nearly did — and you caught it at the last minute.
A patient of mine, a man in his early fifties with metabolic syndrome, a coronary calcium score approaching 3,000, and the kind of vascular age that belongs in someone two decades older, came to a follow-up appointment confused. He had seen his cardiologist the week before. He was doing well. His LDL was 14 mg/dL — the result of years of carefully titrated therapy, a PCSK9 inhibitor added to his statin and ezetimibe because the evidence demanded it and the risk was undeniable. He had no symptoms. No side effects. The plaques were not growing.
But someone had told him his LDL was too low.
He wasn’t sure whether to keep taking his medications. He didn’t know who to believe. He came in holding his lab slip like a question he didn’t know how to ask.
I have thought about that encounter many times. Not just because of what it meant for his cardiovascular risk — though an LDL of 14 versus 70 mg/dL in a man with his risk burden is not a rounding error — but because of what it revealed about how medicine sometimes works against itself.
—
## What the Evidence Actually Says
Let me be direct about the science, because the clinical folklore about “too low” LDL has a stubborn life that is not supported by data.
The Cholesterol Treatment Trialists’ meta-analysis, which pooled data from 26 randomized trials and over 170,000 participants, established the foundational principle clearly: each 1 mmol/L reduction in LDL reduces major cardiovascular events by approximately 22%, proportionally, regardless of baseline level. There is no plateau. There is no floor below which the benefit disappears.¹²
IMPROVE-IT extended this to ezetimibe — adding it to a statin in post-ACS patients reduced LDL further and reduced events further, with no safety signal.² FOURIER did the same for evolocumab, a PCSK9 inhibitor, achieving median LDL of 30 mg/dL with significant reductions in cardiovascular death, MI, and stroke.³ ODYSSEY OUTCOMES confirmed the findings with alirocumab in a high-risk post-ACS population, with some patients achieving LDL levels below 15 mg/dL.⁴
Then came the long-term data. FOURIER-OLE followed patients for nearly nine years. Those who achieved the lowest LDL levels — including sustained levels below 20 mg/dL — had the best outcomes. Not worse. Not neutral. Better. The curves kept separating. This is the “lower longer” principle operationalized in a clinical trial: duration matters, magnitude matters, and the combination of both matters most.⁵
The new 2026 ACC/AHA Dyslipidemia Guidelines — the first comprehensive update in eight years, published in March 2026 — codified this unambiguously. For very high-risk patients, an LDL goal of less than 55 mg/dL is now a Class I recommendation. For select patients at extreme risk, the guidelines endorse pushing further. The language is deliberate: lower for longer provides greater protection.⁶
—
## The Myth of “Too Low”
The concern about very low LDL causing harm — particularly cognitive harm — has been circulating in clinical hallways for years. It deserves a direct response, because the data is not ambiguous.
The EBBINGHAUS trial was designed specifically to evaluate cognition in patients on evolocumab versus placebo. There was no difference in any cognitive outcome. None.⁷ The open-label extension, EBBINGHAUS-OLE, followed patients with sustained very low LDL and reached the same conclusion.⁸
Mendelian randomization studies — which use naturally occurring genetic variants to simulate lifelong exposure to lower LDL — have not found an association between low LDL and dementia or cognitive impairment.⁹ A 2025 meta-analysis of PCSK9 inhibitor trials confirmed no excess risk for neurocognitive events, diabetes, or cancer in patients achieving very low LDL levels.¹⁰
The fear of “too low” LDL is not grounded in evidence. It is a clinical reflex — understandable given how counterintuitive it can feel to push aggressively against a number that is already very low — but it is a reflex, not a data-driven conclusion. When that reflex results in de-intensifying therapy in a patient with a CAC score of 3,000 and an LDL of 14, it is not caution. It is harm.
—
## The Professional Communication Problem
I want to be careful here, because I am not writing to impugn any individual clinician. Cardiology has extraordinary clinicians. The interventionalists who perform revascularization, the electrophysiologists who manage arrhythmias, the heart failure specialists who manage the most complex patients in medicine — these are colleagues I respect deeply.
But something happens in the space between specialists that is rarely discussed: when a clinician unilaterally modifies a care plan built by another specialist, without communicating, without documentation visible to the patient’s full care team, and often based on concerns that the evidence does not support — the patient bears the consequence.
In the case I described, the patient did not know who was right. He was not equipped to evaluate competing claims about LDL safety from clinicians he trusted. He was confused, and that confusion was entirely a product of a system failure, not a knowledge deficit on his part. He was doing everything right. The system let him down.
I am a board-certified lipidologist. Lipid management is a board-certified subspecialty. When a specialist who is not trained in lipidology changes lipid therapy I have carefully structured — without communicating, without raising the question in a shared note, without even a message to the patient’s care team — and when that change is based on a concern the evidence does not support, it crosses a line. Not a personal line. A professional one. It is a failure of collaborative care that creates clinical risk.
That is a culture problem.
—
## What Collaborative Care Actually Requires
Collaboration is not a soft skill. It is a clinical competency, and in complex patients it is a patient safety issue.
Genuine collaborative care requires several things that are largely absent from how medicine currently operates. It requires communication before changing another specialist’s management, not after or never. It requires shared documentation that surfaces disagreements to the care team rather than obscuring them from patients and colleagues. It requires a shared commitment to the evidence base — not consensus for its own sake, but a willingness to update practice when the data changes.
It also requires intellectual humility. The clinician who is not a lipidologist expressing concern about LDL levels below 20 should first ask: what does the evidence show? Not what does it feel like intuitively, not what did a senior colleague say during training fifteen years ago, but what does the peer-reviewed evidence published in this decade show?
When I raised this question in a large academic health system — when I tried to build the infrastructure for coordinated, evidence-based lipid and cardiometabolic management at scale — I encountered what I now recognize as a familiar pattern: institutional inertia, hierarchical resistance, and the deeply human tendency to defend existing practice against incoming evidence. It is not unique to any person or institution. It is a feature of how large systems preserve their own stability, often at the cost of the patients they serve.
—
## A Note to Patients
If you are managing cardiovascular risk and you have received conflicting guidance from different clinicians about your LDL — whether to push it lower, whether a very low level is dangerous, whether to stop or reduce a medication because your LDL is “too low” — please know the following:
The evidence does not support the concept of “too low” LDL in high-risk patients. Clinical trials with nearly a decade of follow-up have found that lower LDL levels, sustained over time, produce better cardiovascular outcomes without meaningful increases in cognitive impairment, cancer, or other harms. The 2026 ACC/AHA Guidelines have codified this.
Ask your clinician where the concern comes from. Ask them to point to the evidence. You are entitled to that conversation, and a good clinician will welcome it.
If you are receiving conflicting guidance from multiple clinicians and no one is reconciling it, that is not a personal failing. It is a gap in how your care is coordinated. You deserve a care team that talks to each other.
—
## A Closing Thought for Clinicians
The most important line in the new ACC/AHA guidelines may not be about a specific LDL target. It may be the implicit premise behind the entire document: that we now have the tools, the evidence, and the pharmacology to dramatically reduce cardiovascular events in the highest-risk patients — if we use them consistently, if we communicate across specialties, and if we keep the evidence rather than clinical mythology at the center of the conversation.
The question is not whether lower is better. The evidence on that is settled. The question is whether we are organized — professionally and culturally — to act on what we know.
—
## References
1. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670–1681.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). *N Engl J Med.* 2015;372(25):2387–2397.
3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). *N Engl J Med.* 2017;376(18):1713–1722.
4. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). *N Engl J Med.* 2018;379(22):2097–2107.
5. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). *Circulation.* 2023;147(16):1192–1203.
6. Blumenthal RS, Morris PB, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. *J Am Coll Cardiol.* Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
7. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab (EBBINGHAUS). *N Engl J Med.* 2017;377(7):633–643.
8. Giugliano RP, Keech AC, Murphy SA, et al. Long-term cognitive safety of achieving very low LDL cholesterol with evolocumab (EBBINGHAUS-OLE). *NEJM Evidence.* 2025. doi:10.1056/EVIDoa2400112
9. Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REGARDS Study. *Circulation.* 2018;137(12):1260–1269.
10. Rasheed A, Sultan M, Tahir A, et al. Safety and efficacy of achieving very low LDL cholesterol concentrations with PCSK9 inhibitors: a meta-analysis. *J Clin Med.* 2025;14(13):4562.
11. Johnson AE, Swabe GM, Bress AP, et al. Real-world prescribing in accordance with ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD. *Am J Prev Cardiol.* 2025.
12. Nissen SE, Bhatt DL. How low can you go? New evidence supports no lower bound to LDL-C level in secondary prevention [editorial]. *Circulation.* 2023;147(16):1204–1207.
—
*Anthony Pick, MD, CDCES, CCD is a board-certified endocrinologist, obesity medicine specialist, lipidologist, and cardiometabolic lifestyle medicine specialist practicing at True Health (www.truehealth.co) in Deerfield, Illinois, where he leads cardiometabolic and endocrine services. He writes about metabolic medicine, evidence-based practice, and healthcare delivery at Optimized Medicine on Substack.